Chemotherapy of Cholangiocarcinoma: Current Management and Future Directions

J. Jo, S. Song
{"title":"Chemotherapy of Cholangiocarcinoma: Current Management and Future Directions","authors":"J. Jo, S. Song","doi":"10.5772/INTECHOPEN.76134","DOIUrl":null,"url":null,"abstract":"Cholangiocarcinoma is a relatively rare form of gastroenterological cancer that divided into intrahepatic, perihilar, and distal bile duct cancer. Approximately, 10,000 new cases are diagnosed annually in the United States, and a 5-year survival rate is below 20%. While only surgical resection can provide a cure, most of cholangiocarcinomas are detected at inoperable stage and associated with poor prognosis. Moreover, cholangiocarcinoma has a high recurrence rate, even after curative surgery. Therefore, chemotherapy has an important role in the treatment of patients with cholangiocarcinoma. International efforts by physicians and researchers are revealing genetic factors of cholangiocarcinoma progression, which will identify early diagnostic markers and novel therapeutic targets. In this chapter, current strategies of adjuvant, neoadjuvant, and palliative chemotherapy will be discussed, as well as expectant future therapeutic targets and development of individualized therapies.","PeriodicalId":385968,"journal":{"name":"Topics in the Surgery of the Biliary Tree","volume":"35 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in the Surgery of the Biliary Tree","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.76134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Cholangiocarcinoma is a relatively rare form of gastroenterological cancer that divided into intrahepatic, perihilar, and distal bile duct cancer. Approximately, 10,000 new cases are diagnosed annually in the United States, and a 5-year survival rate is below 20%. While only surgical resection can provide a cure, most of cholangiocarcinomas are detected at inoperable stage and associated with poor prognosis. Moreover, cholangiocarcinoma has a high recurrence rate, even after curative surgery. Therefore, chemotherapy has an important role in the treatment of patients with cholangiocarcinoma. International efforts by physicians and researchers are revealing genetic factors of cholangiocarcinoma progression, which will identify early diagnostic markers and novel therapeutic targets. In this chapter, current strategies of adjuvant, neoadjuvant, and palliative chemotherapy will be discussed, as well as expectant future therapeutic targets and development of individualized therapies.
胆管癌的化疗:目前的管理和未来的方向
胆管癌是一种相对罕见的消化道肿瘤,可分为肝内、肝门周围和远端胆管癌。在美国,每年大约有10,000个新病例被诊断出来,5年生存率低于20%。虽然只有手术切除才能治愈胆管癌,但大多数胆管癌是在不能手术的阶段发现的,预后较差。此外,胆管癌有很高的复发率,即使在治愈性手术后。因此,化疗在胆管癌患者的治疗中具有重要的作用。国际上的医生和研究人员正在努力揭示胆管癌进展的遗传因素,这将确定早期诊断标记和新的治疗靶点。在本章中,将讨论当前的辅助、新辅助和姑息性化疗策略,以及对未来治疗靶点和个体化治疗发展的预期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信